These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 14715048)

  • 1. Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.
    Baptista T; Kin NM; Beaulieu S
    Clin Pharmacokinet; 2004; 43(1):1-15. PubMed ID: 14715048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness.
    Kouidrat Y; Amad A; De Hert M
    Curr Pharm Des; 2015; 21(23):3317-24. PubMed ID: 26088113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs.
    Buzea CA; Manu P; Dima L; Correll CU
    Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):729-744. PubMed ID: 36369828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin-Induced Type 1 Hypersensitivity in a Child with Antipsychotic-Induced Weight Gain.
    Mennella C; Dickstein DP
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):106-107. PubMed ID: 27548055
    [No Abstract]   [Full Text] [Related]  

  • 5. Metformin for Antipsychotic-Related Metabolic Syndrome in Children: Fact or Fiction?
    Naguy A; El-Sori D
    Chin Med J (Engl); 2018 Jun; 131(12):1490-1491. PubMed ID: 29893366
    [No Abstract]   [Full Text] [Related]  

  • 6. Loxapine for Reversal of Antipsychotic-Induced Metabolic Disturbances: A Chart Review.
    Jain S; Andridge R; Hellings JA
    J Autism Dev Disord; 2016 Apr; 46(4):1344-53. PubMed ID: 26687568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactics of erectile dysfunction in patients with metabolic syndrome.
    Gamidov SI; Mazo EB; Gasanov RV; Sotnikova EM
    Bull Exp Biol Med; 2009 Aug; 148(2):318-21. PubMed ID: 20027358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics.
    Jesus C; Jesus I; Agius M
    Psychiatr Danub; 2015 Sep; 27 Suppl 1():S489-91. PubMed ID: 26417824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug interactions in the elderly with diabetes mellitus].
    Hendrychová T; Vlček J
    Vnitr Lek; 2012 Apr; 58(4):299-304. PubMed ID: 22559804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.
    Fichtenbaum CJ; Gerber JG
    Clin Pharmacokinet; 2002; 41(14):1195-211. PubMed ID: 12405866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications.
    Russell JM; Mackell JA
    CNS Drugs; 2001; 15(7):537-51. PubMed ID: 11510624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?
    Aichhorn W; Whitworth AB; Weiss EM; Marksteiner J
    Drug Saf; 2006; 29(7):587-98. PubMed ID: 16808551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of melatonin in reducing second-generation antipsychotic metabolic effects: A double blind controlled clinical trial.
    Agahi M; Akasheh N; Ahmadvand A; Akbari H; Izadpanah F
    Diabetes Metab Syndr; 2018; 12(1):9-15. PubMed ID: 28847468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present recommendations in type 2 diabetes treatment.
    Lebovitz HE
    Endocrinol Nutr; 2009 Dec; 56 Suppl 4():46-9. PubMed ID: 20629232
    [No Abstract]   [Full Text] [Related]  

  • 18. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
    Hasnain M; Fredrickson SK; Vieweg WV
    J Psychopharmacol; 2011 Jun; 25(6):715-21. PubMed ID: 21169390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions.
    Andrade C
    J Clin Psychiatry; 2016 Sep; 77(9):e1090-e1094. PubMed ID: 27780328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.